XORTX Therapeutics (XRTX) Q4 2024 earnings summary

Executive summary

• Auditors issued an unqualified opinion for 2024, confirming fair presentation under IFRS, with a material uncertainty regarding going concern due to recurring operating losses and the need for additional financing to sustain operations.

• The company focuses on late-stage clinical development of therapies for gout and kidney diseases, with ongoing R&D and regulatory milestones.

Financial highlights

• Cash decreased to $2.47M at year-end 2024 from $3.45M in 2023, reflecting continued operating losses and R&D spending.

• Net loss for 2024 was $3.31M, compared to $2.16M in 2023 and $7.72M in 2022.

• Total assets declined to $4.09M from $5.47M year-over-year.

• Shareholders’ equity fell to $3.34M from $4.64M year-over-year.

• Weighted average shares outstanding increased to 2.88M in 2024 from 1.98M in 2023.

Outlook and guidance

• Management plans to raise additional capital to fund ongoing R&D and clinical trials, with uncertainty about future financing casting doubt on the ability to continue as a going concern.

• Product development and regulatory approvals remain key milestones for future revenue generation.